Study treatment
DISEASE
Treatment consisted of escalating doses of plitidepsin 3‐h intravenous (i.v.) infusion Day 1 and 15, and BTZ subcutaneous bolus injection Day 1, 4, 8, and 11, with fixed DXM dose 40.0 mg orally Day 1, 8, 15, and 22, all every 4 weeks (q4wk), for a maximum of 8 cycles. If response or disease stabilization was observed, treatment after Cycle 8 could continue with plitidepsin and DXM at the same doses. Antiemetic prophylaxis was given to all patients, consisting of ondansetron 8 mg i.v. or equivalent, diphenhydramine hydrochloride 25 mg i.v. or equivalent, and ranitidine 50 mg i.v. or equivalent administered 30 min before each plitidepsin infusion. If necessary, 10 mg of metoclopramide every 8 h could be administered after the end of plitidepsin infusion or the duration of treatment with serotonin antagonists could be extended.